COVID in patients with antibody deficiency (COV-AD)

Project summary:

Individuals with antibody deficiency are prone to infectious diseases, respond poorly to existing vaccines and are particularly vulnerable to poor outcomes following SARS-CoV-2 infection.

COVID in patients with antibody deficiency (COV-AD) is a multi-site United Kingdom study that aims to:

i) determine the prevalence of asymptomatic and symptomatic SARS-CoV-2 infection in patients with primary and secondary antibody deficiency,

ii) determine how frequently SARS-CoV-2 viral persistence occurs in patients with primary and secondary antibody deficiency and

iii) characterise the immune response of these patients following SARS-CoV-2 infection and vaccination. 

Study participants will be invited to submit a nasopharyngeal swab at study entry to determine asymptomatic/chronic viral carriage and serial swabs should the test positive during the course of the study which will be subject to viral sequencing. Antibody and T cell responses following infection and vaccination will be studied using ELISA and ELISPOT assays respectively. PBMCs will be stored for further detailed immunological analysis of vaccine responders and non-responders.

Funders

UK Research and Innovation

Leader researcher:

Professor Alex Richter and Professor Siobhan Burns

Lead institution:

University of Birmingham

Vaccine type:

AstraZeneca
Moderna
Pfizer

Recruitment for clinical trial open:

Yes

Website:

Find out more about COV-AD